acute myeloid leukaemia
Moleculin secures EMA approval to expand acute myeloid leukaemia trial across EU
May 16, 2025Research and Development Clinical Trial Application (CTA), European Union (EU), FDA, Food and Drug Administration, Moleculin Biotech, Oncology, Orphan Drug Designation (ODD), acute myeloid leukaemia
Moleculin Biotech has received approval from the European Medicines Agency (EMA) to expand its phase 3 ‘MIRACLE’ trial into nine …
Oryzon Genomics announces publication of phase 2a ALICE trial results
June 4, 2024Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial
Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
Daiichi Sankyo’s Vanflyta approved by EC for acute myeloid leukaemia treatment
November 10, 2023Medical Communications Daiichi Sankyo, EC, EU, Oncology, Vanflyta, acute myeloid leukaemia
Daiichi Sankyo has announced that Vanflyta (quizartinib) has been approved in the EU for combination use with standard cytarabine and …
Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia
July 16, 2020Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib
NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …
NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia
January 23, 2020Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia
The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …
Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia
December 11, 2019Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma
Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …
Living with acute myeloid leukaemia
September 23, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute myeloid leukaemia, feature, patient experience, pharma
Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …
Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018
December 5, 2018Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma
Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …
Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia
November 8, 2018Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma
Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …
NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia
October 8, 2018Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma
NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …
Jazz Pharma’s acute myeloid leukaemia drug scores EU approval
August 29, 2018Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma
Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …
Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no
December 6, 2017Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma
Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …
Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis
September 20, 2017Research and Development, Sales and Marketing EU, Europe, Novartis, acute myeloid leukaemia, advanced systemic mastocytosis, pharma, pharmaceutical
Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …
FDA approves Celgene and Agios’ acute myeloid leukaemia drug
August 2, 2017Research and Development, Sales and Marketing Celgene, FDA, Idhifa, acute myeloid leukaemia, agios, biotech, drugs, life sciences, medicines, pharma, pharmaceuticals
The FDA has given its approval for the commercialisation of Celgene and Agios Pharmaceutical’s Idhifa for the treatment of relapsed …
New drug combination gives hope for acute myeloid leukaemia treatment
March 8, 2017Research and Development acute myeloid leukaemia
A new trial in the US hopes to marry a new pair of drugs as a combination treatment for acute …
Latest content
Five Facts about cardiovascular disease
